Oprea Eliza, Cinteza Delia, Berteanu Mihai, Manolescu Bogdan Nicolae
University of Bucharest, Faculty of Chemistry, Department of Organic Chemistry, Biochemistry and Catalysis, Bucharest, Romania.
"Carol Davila" University of Medicine and Pharmacy, Faculty of Medicine, Department of Rehabilitation and Physical Medicine, Bucharest, Romania.
Maedica (Bucur). 2013 Sep;8(3):249-55.
Diabetes mellitus is one of the most frequent stroke-related comorbid states, and it is characterized by accumulation of reactive carbonyl compounds (RCOs), leading to "carbonyl stress". This pilot study was aimed to evaluate the effect of the consumption of the nutritional supplement ALAnerv(®) on some serum carbonyl stress markers, as well as on the activity of erythrocytes' glyoxalases in post-acute stroke patients undergoing rehabilitation.
We created a study population of 28 patients, organized into (-) ALA and (+) ALA groups. Patients from (+) ALA group received ALAnerv(®) for two weeks (2 pills/day). All the subjects followed the same rehabilitation program. In both groups, blood samples were taken at the hospitalization and at the discharge moments, respectively. On these samples we assessed lactic acid, fructosamine and RCOs concentrations, as well as the activities of glyoxalases 1 and 2 from erythrocytes' lysates.
In (-) ALA group the concentrations of fructosamine and RCOs significantly increased (0.90 ± 0.04 vs. 1.02 ± 0.04, p = 0.020; 0.19 ± 0.03 vs. 0.28 ± 0.07, p = 0.027) during the study period. Also, glyoxalase 2 activity decreased in this group (27.04 ± 6.10 vs. 14.43 ± 3.02, p = 0.027). In (+) ALA group, the variation of these parameters did not reach statistical significance. Only, the activity of Glo1, which catalyzes the rate-limiting step in the glyoxalase pathway, had an increasing trend in (+) ALA group. The percentage of variation of fructosamine between (-) ALA and (+) ALA groups reached statistical significance (14.8 ± 5.2 vs. - 1.0 ± 13.3, p = 0.047). Regression analysis indicated that the activity of glyoxalase 2 was significantly influenced by the treatment with ALAnerv(®) (p < 0.001), while the concentration of RCOs was significantly influenced by diabetes mellitus (p = 0.030).
Our preliminary results suggest that ALAnerv(®) could be useful for the correction of the carbonyl stress status in post-acute stroke patients with diabetes. Also, this study underlines the need of a longer treatment period with a higher dose.
糖尿病是与中风相关的最常见合并症之一，其特征是活性羰基化合物（RCOs）积累，导致“羰基应激”。这项初步研究旨在评估营养补充剂ALAnerv(®)对急性中风后康复患者血清中某些羰基应激标志物以及红细胞乙二醛酶活性的影响。
我们建立了一个由28名患者组成的研究群体，分为（-）ALA组和（+）ALA组。（+）ALA组的患者服用ALAnerv(®)两周（每天2粒）。所有受试者都遵循相同的康复计划。在两组中，分别在住院时和出院时采集血样。对这些样本，我们评估了乳酸、果糖胺和RCOs的浓度，以及红细胞裂解液中乙二醛酶1和2的活性。
在研究期间，（-）ALA组的果糖胺和RCOs浓度显著增加（0.90±0.04对1.02±0.04，p = 0.020；0.19±0.03对0.28±0.07，p = 0.027）。此外，该组乙二醛酶2的活性下降（27.04±6.10对14.43±3.02，p = 0.027）。在（+）ALA组中，这些参数的变化未达到统计学意义。仅催化乙二醛酶途径限速步骤的Glo1活性在（+）ALA组有上升趋势。（-）ALA组和（+）ALA组之间果糖胺的变化百分比达到统计学意义（14.8±5.2对-1.0±13.3，p = 0.047）。回归分析表明，乙二醛酶2的活性受ALAnerv(®)治疗的显著影响（p < 0.001），而RCOs的浓度受糖尿病的显著影响（p = 0.030）。
我们的初步结果表明，ALAnerv(®)可能有助于纠正急性中风后糖尿病患者的羰基应激状态。此外，本研究强调需要更长的治疗期和更高的剂量。
